imiquimod
Trade name: aldara
Approved
Feb 27, 1997
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear during treatment. Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production. It is not used on warts inside the vagina, penis, or rectum. Imiquimod is also used to treat a skin condition of the face and scalp called actinic keratoses. Imiquimod can also be used to treat certain types of skin cancer called superficial basal cell carcinoma. Imiquimod is particularly useful on areas where surgery or other treatments may be difficult, complicated or otherwise undesirable, especially the face and lower legs. Imiquimod's mechanism of action is via stimulation of innate and acquired immune responses, which ultimately leads to inflammatory cell infiltration within the field of drug application followed by apoptosis of diseased tissue. Imiquimod does not have direct antiviral activity. Studies of mice show that imiquimod may induce cytokines, including interferon-alpha (IFNA) as well as several IFNA genes (IFNA1, IFNA2, IFNA5, IFNA6, and IFNA8) as well as the IFNB gene. Imiquimod also induced the expression of interleukin (IL)-6, IL-8, and tumor necrosis factor alpha genes. In the treatment of basal cell carcinoma, Imiquimod appears to act as a toll-like receptor-7 agonist, and is thought to exert its anti-tumor effect via modification of the immune response and stimulation of apoptosis in BCC cells. In treating basal cell carcinoma it may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion. Imiquimod is used for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Also indicated for the treatment of external genital and perianal warts/condyloma acuminata in individuals 12 years old and above. — NCATS
Clinical trial activity
163 trials · 158 clinical orgs · 17 marketing orgs
Earliest trial started Jun 1, 1999 (NCT00031759)
Timeline
1990s
- Feb 27, 1997
Earliest FDA Approval
- Feb 27, 1997
Medicis — NDA Secondary Org
- Feb 27, 1997
Bausch Health Companies — Marketing Organization
- Feb 27, 1997
Bausch Health Companies — NDA Secondary Org
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
2010s
- Feb 25, 2010
Fougera — Marketing Organization
- Sep 7, 2010
Padagis Us — Marketing Organization
- Sep 7, 2010
Perrigo — Marketing Organization
- Feb 28, 2011
ANDA Repository — Marketing Organization
- Feb 28, 2011
Encube Ethicals Pvt. Ltd. — Marketing Organization
- Mar 24, 2011
Graceway — NDA Secondary Org
- Apr 15, 2011
Taro Pharmaceuticals — Marketing Organization
- Apr 15, 2011
Sun Pharmaceuticals — Marketing Organization
- Apr 18, 2011
Cosette — Marketing Organization
- Apr 18, 2011
G & W Laboratories Inc. — Marketing Organization
- Apr 18, 2011
ACP Nimble — Marketing Organization
- Mar 6, 2012
Glenmark Pharmaceuticals — Marketing Organization
- Apr 6, 2012
Apotex — Marketing Organization
- Jun 24, 2014
Strides Pharma Science — Marketing Organization
Indications
Approved for
Studied for
- Alopecia Areata · Phase 4
- Anus Neoplasms · Phase 3
- Astrocytoma · Phase 1
- Basal Cell Carcinoma · Phase 4
- Biomarkers · Phase 4
- Bowen's Disease · Phase 2/Phase 3
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma in Situ · Phase 2
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Ovarian Epithelial · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Cervical Intraepithelial Neoplasia · Phase 3
- Cheilitis · Phase 4
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Condylomata Acuminata · Phase 4
- Diffuse Intrinsic Pontine Glioma · Phase 1
- Ependymoma · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Genital Neoplasms, Female · Phase 2
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Hamartoma · Phase 2
- Healthy Volunteers · Phase 1
- Hemangioma, Capillary · Phase 2
- Hepatitis B · Phase 2/Phase 3
- HIV · Phase 4
- HIV Infections · Phase 3
- Human papillomavirus 16 · Phase 2
- Hutchinson's Melanotic Freckle · Phase 4
- Hyperplasia · Phase 4
- Inflammatory Bowel Diseases · Phase 2/Phase 3
- Influenza, Human · Phase 4
- Influenza in Birds · Phase 1
- Influenza Vaccines · Phase 2
- Keloid · Phase 2
- Keratosis · Phase 4
- Leishmaniasis, Cutaneous · Phase 3
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukoplakia · Phase 1/Phase 2
- Liver Cirrhosis · Phase 2
- Lymphoma, T-Cell, Cutaneous · Early Phase 1
- Malaria, Falciparum · Early Phase 1
- Medulloblastoma · Phase 1
- Melanoma · Phase 3
- Microsatellite Instability · Phase 1
- Mouth Neoplasms · Early Phase 1
- Mycosis Fungoides · Early Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 4
- Neoplasms, Squamous Cell · Phase 1
- Neurofibroma · Phase 1
- Neurofibromatosis 1 · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 2
- Paget Disease, Extramammary · Phase 3
- Papillomaviridae · Phase 4
- Papillomavirus Infections · Phase 3
- Port-Wine Stain · Phase 2
- Precancerous Conditions · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1/Phase 2
- Prostatic Neoplasms · Phase 1
- Renal Insufficiency · Phase 2/Phase 3
- Sarcoma · Phase 1
- Scleroderma, Localized · Phase 3
- Skin Neoplasms · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Early Phase 1
- Squamous Intraepithelial Lesions · Phase 4
- Stomach Neoplasms · Phase 1
- Urinary Bladder · Phase 1
- Urinary Bladder Neoplasms · Phase 2
- Uterine Cervical Dysplasia · Phase 2
- Uterine Cervical Neoplasms · Phase 2
- Vaccination · Phase 2
- Vaccines · Phase 2
- Vagina · Phase 4
- Vaginal Diseases · Phase 2
- Vaginal Neoplasms · Phase 2
- Vulvar Neoplasms · Phase 3
- Warts · Phase 4
Mechanism of action
- Toll-like receptor 7AGONIST
TLR7 agonist
Approval history
- approvedFeb 27, 1997
Chemistry & pharmacology
SMILES
CC(C)CN1C=NC2=C1C3=C(C=CC=C3)N=C2N- Mol. weight
- 240.3036 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Prescription Only
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaImiquimod ↗
- NCATSP1QW714R7M ↗
- ChEMBLCHEMBL1282 ↗
Also known as
- 1h-imidazo(4,5-c)quinolin-4-amine, 1-(2-methylpropyl)-
- 1-isobutyl-1h-imidazo(4,5-c)quinolin-4-amine
- 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-amine
- 1-isobutyl-1h-imidazo[4,5-c]quinolin-4-amine
- 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline
- 4-amino-1-isobutyl-1h-imidazo(4,5-c)quinoline
- aldara
- aldara
- aldara
- aldara
- aldara
- aldara
- beselna
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimod
- imiquimodum
- imiquimodum
- imiquinod
- r 837
- r 837
- r 837
- r-837
- r-837
- r-837
- s 26308
- s-26308
- s-26308
- s-26308
- tmx-101
- tmx-101
- zartra
- zartra
- zyclara
- zyclara
- zyclara
- zyclara
- zyclara
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07251413 | Phase 1/Phase 2 (Phase 2) | Oct 22, 2025 | Institute of Oncology Dr. Rosell (IOR), Regeneron, University of Barcelona |
| NCT07210775 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2025 | University of Southern California |
| NCT06840470 | Phase 4 | Mar 31, 2025 | University of Michigan |
| NCT06686043 | Phase 2 | Aug 23, 2024 | Baylor University |
| NCT06411106 | N/A | Jun 30, 2024 | Leiden University |
| NCT06356012 | Phase 4 | Apr 2, 2024 | Barretos Cancer Hospital, Farmoquimica S.A., Fundação de Amparo à Pesquisa do Estado de São Paulo, Hospital de Cancer de Barretos - Fundacao Pio XII |
| NCT05838599 | Early Phase 1 (Phase 1) | Jul 1, 2023 | Northwestern University |
| NCT05212246 | Phase 3 | Apr 1, 2023 | Department of Veteran Affairs |
| NCT05740969 | Phase 2 | Feb 1, 2023 | University of Copenhagen |
| NCT05468606 | Early Phase 1 (Phase 1) | Jan 31, 2023 | Leiden University |
| NCT05375903 | Phase 1 | Jun 1, 2022 | UroGen Pharma |
| NCT05315024 | N/A | Apr 30, 2022 | The University of Hong Kong |
| NCT05314127 | Phase 2 | Apr 15, 2022 | Zagazig University |
| NCT05055050 | Phase 1 | Feb 28, 2022 | University of Texas at Houston |
| NCT04808245 | Phase 1 | Dec 6, 2021 | Deutsche Krebshilfe e.V., German Cancer Research Center, Humboldt University, Johannes Gutenburg University, Roche |
| NCT05028322 | Phase 2 | Nov 1, 2021 | University of Lorraine |
| NCT04883645 | Early Phase 1 (Phase 1) | Sep 30, 2021 | Columbia University |
| NCT04842422 | Phase 4 | Apr 16, 2021 | Medical University of Graz |
| NCT04143451 | Phase 3 | Oct 23, 2019 | The University of Hong Kong |
| NCT04116320 | Phase 1 | Oct 8, 2019 | Theraclion, University of Virginia |
Organizations
Research & Development (158)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Graceway | For profit | 16 | 10 | 4 | 2001 |
| National Cancer Institute (NCI) | Government | 16 | 2 | 4 | 1999 |
| Meda | For profit | 10 | 8 | 3 | 2001 |
| The University of Hong Kong | Academic/Hospital | 7 | 7 | 2 | 2012 |
| Maastricht University | Academic/Hospital | 6 | 4 | 3 | 2014 |
| University of Minnesota | Academic/Hospital | 5 | 4 | 2 | 2000 |
| 3M | For profit | 4 | 0 | 2 | 2000 |
| Medical University of Graz | Academic/Hospital | 4 | 3 | 2 | 2011 |
| National Institutes of Health (NIH) | Government | 4 | 0 | 3 | 2004 |
| University of Tuebingen | Academic/Hospital | 4 | 4 | 2 | 2002 |
| University of Vienna | Academic/Hospital | 4 | 4 | 3 | 2008 |
| Actavis | For profit | 3 | 3 | 2 | 2008 |
| Department of Veteran Affairs | Government | 3 | 3 | 3 | 2007 |
| Leiden University | Academic/Hospital | 3 | 2 | 3 | 2015 |
| Mayo Clinic | Academic/Hospital | 3 | 1 | 2 | 1999 |
| New York University | Academic/Hospital | 3 | 2 | 2 | 2005 |
| United States Navy | Government | 3 | 3 | 3 | 2004 |
| University of Pittsburgh | Academic/Hospital | 3 | 3 | 2 | 2012 |
| University of Virginia | Academic/Hospital | 3 | 3 | 1 | 2004 |
| AIDS Malignancy Consortium | Academic/Hospital | 2 | 2 | 1 | 2014 |
Marketing (21)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| 3M | For profit | NDA | — |
| 3M | For profit | IND | — |
| ACP Nimble | For profit | MKTG | Apr 18, 2011 |
| ANDA Repository | For profit | MKTG | Feb 28, 2011 |
| Apotex | For profit | MKTG | Apr 6, 2012 |
| Bausch Health Companies | For profit | MKTG | Feb 27, 1997 |
| Bausch Health Companies | For profit | NDA2 | Feb 27, 1997 |
| Cosette | For profit | MKTG | Apr 18, 2011 |
| Encube Ethicals Pvt. Ltd. | For profit | MKTG | Feb 28, 2011 |
| Fougera | For profit | MKTG | Feb 25, 2010 |
| G & W Laboratories Inc. | For profit | MKTG | Apr 18, 2011 |
| Glenmark Pharmaceuticals | For profit | MKTG | Mar 6, 2012 |
| Glenmark Pharmaceuticals | For profit | SYN | Mar 6, 2012 |
| Glenmark Pharmaceuticals | For profit | SYN | Mar 6, 2012 |
| Graceway | For profit | NDA2 | Mar 24, 2011 |
| Medicis | For profit | NDA2 | Feb 27, 1997 |
| Padagis Us | For profit | MKTG | Sep 7, 2010 |
| Perrigo | For profit | MKTG | Sep 7, 2010 |
| Strides Pharma Science | For profit | MKTG | Jun 24, 2014 |
| Sun Pharmaceuticals | For profit | MKTG | Apr 15, 2011 |
| Taro Pharmaceuticals | For profit | MKTG | Apr 15, 2011 |